Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, has announced the launch of its ALISCA™-Breast1 Phase II trial (PUMA-ALI-1201; NCT06369285). The study will evaluate alisertib, in combination with endocrine therapy, for the treatment of hormone receptor-positive (HR+), HER2-negative recurrent or…
Tanner Cancer Care’s newly expanded Roy Richards, Sr. Cancer Center is not only visually impressive but also features the latest advancements in cancer treatment technology. Tanner Cancer Care’s newly expanded Roy Richards, Sr. Cancer Center is now the first community…
Pharmanovia, a global pharmaceutical company focused on commercializing innovative medicines and revitalizing established ones, today announced the expansion of its oncology portfolio with a new licensing agreement for catumaxomab. This agreement will enable the treatment of malignant ascites, a rare…
A recent study published in Heart Rhythm highlights how artificial intelligence (AI) algorithms embedded in Medtronic’s LINQ II implantable loop recorders (ILRs) significantly reduce alert and episode burdens. This is achieved through data analysis powered by PaceMate’s flagship product, PaceMateLIVE™.…
While every company wants to support their employees’ health, businesses of all sizes face challenges with rising healthcare costs and complex, confusing benefit plans. Prescription medications can be a tough challenge for many people. Faced with the decision of whether…
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a leader in genomic medicine, today announced that the U.S. Food and Drug Administration (FDA) has approved the investigational new drug (IND) application for its ST-503 program. ST-503 is an experimental epigenetic regulator being developed…
Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a leading biotechnology company focused on developing genetic therapies for rare, life-threatening diseases, announced promising long-term safety and efficacy data from its Phase 1 RP-A501 study. The results were presented at the 2024 American Heart…
Encora Therapeutics is excited to announce the successful completion of the ULTRE (Upper Limb Tremor Reduction in Essential Tremor) clinical trial. The study assessed the safety, tolerability, and effectiveness of Encora’s innovative wrist-worn stimulation device for individuals with essential tremor…
Vir Biotechnology, Inc. (NASDAQ:VIR) today revealed positive results from the SOLSTICE Phase 2 clinical trial evaluating its investigational combination of tobevibart and elebsiran for the treatment of chronic hepatitis delta (CHD). The trial, which included both monotherapy and combination therapy…
HistoSonics, the developer of the Edison® Histotripsy System, has announced the enrollment of the first patients in its novel BOOMBOX study, a prospective master protocol designed to assess the real-world application of histotripsy for treating liver tumors. This post-market study…
Lobe Sciences, Ltd. (CSE: LOBE, OTCQB: LOBEF) and Alera Pharma, Inc. today announced the receipt of a second patent allowance for their Conjugated Psilocin™ technology. The patent, titled “Stable Psilocin Salts, Esters, and Conjugates and Uses Thereof,” covers compositions that…
SOLVD Health, a patient intelligence company focused on precision solutions to improve health outcomes, has launched a comprehensive post-approval study for AvertD®, the first FDA-approved genetic test to assess the risk of opioid use disorder (OUD). The study will build…